|By Patrick Crutcher|
|Thursday, 03 March 2011 01:58|
Cleveland BioLabs Inc.(NASDAQ: CBLI) looks primed to hear news about a government grant related to their CBLB502 program. In just the past few weeks, the US Biomedical Advanced Research and find cialis online Development Authority (BARDA) has filled several contracts that had been expected for sometime. It appears that BARDA-HHS is finally making it’s way through their backlog of applications and buy propecia no prescription getting funding out there. In CBLI’s recent presentation at BIO CEO, management noted that they expect a grant from BARDA-HHS to be over $50 million. We think that more financial commitment from the US government could eventually lead to foreign development contracts with countries like Israel. This grant also sets them up for a potential buying Request for Proposal(RFP) from BARDA for a radiation countermeasure later this year. Of companies competing for these contracts, CBLI is by far the most advanced program in this field, in terms of their lead drug and viagra online generic time to market. Their treatment protects 2 important body systems, the blood and buy viagra gastrointestinal(GI) tract, that are crucial to improving survival in ARS. All of this additional funding will help CBLI further support CBLB502 thru development in acute-radiation syndrome(ARS) to eventual FDA approval and canadian viagra online stockpiling.
Aastrom Biosciences (NASDAQ: ASTM) is a stem-cell company that has a few upcoming catalysts that should get some attention. In relation to their autologous cell therapy in patients with critical limb ischemia (CLI), we expect an update on their SPA negations for “no option” CLI patients and full 12-month amputation-free survival results from the Phase 2b study in the second quarter, as the last of patient follow-ups is in March. These Phase 2b 12-month AFS results should give us a clearer picture of efficacy, as they had an unusually low event rate in the placebo arm at 6 months. They will be conducting two Phase 3 trials of their TRCs in CLI, one for those at are “no option” and one for “poor option”. Management expects to begin the Phase 3 trial in “no-option” patients in the second quarter. The second Phase 3 trial will likely start later in 2011. This program has received Fast Track designation from the FDA.
Later this year, we also expect to hear 12-month data from the Phase 2 IMPACT-DCM trial and 6-month results from the DCM Catheter Phase 2 in 3Q-2011. We also anticipate the initiation of a Phase 2b in DCM (Catheter) later in the year, closer to 4Q. Aastrom has adequate cash on hand for 2011; they ended 2010 with about $31 million in cash. Positive outcomes from the 12-month AFS data and FDA SPA negotiations could make their partnership prospects more fruitful in 2011.
Spectrum Pharmaceuticals (NASDAQ: SPPI) has an upcoming dance with the FDA for their sNDA for FUSILEV (levo-leucovorin) for use in advanced metastatic colorectal cancer (mCRC) patients and a Zevalin label adjustment request. SPPI received a CRL for their FUSILEV sNDA back in October 2009, with the FDA citing that their sNDA "did not demonstrate that FUSILEV is non-inferior to leucovorin." In brief, FUSILEV contains the active isomer of leucovorin, which is used to protects against the toxic effects of methotrexate, a chemotherapy agent. No new trial data was submitted for the FUSILEV sNDA, a decision which was based on their meeting with the FDA in January 2010. The expectation among analysts is that the FDA will approve the sNDA this time around. This seems likely given the shortages of leucovorin, approval status in mCRC in the EU for over a decade and its’ status as a reimbursable alternative to the generic for mCRC. Current shortages from generic suppliers of leucovorin helped boost their anticipated revenue for 4Q and FY2010, due to increased sales of FUSILEV.
On January 20th, they submitted a request to have the bioscan requirement removed from the Zevalin label; an FDA response is expected within 60 days. Zevalin is an FDA-approved and currently marketed for the treatment of non-Hodgkin’s lymphoma (NHL). Many see Zevalin as the main valuation driver over the next 12-24 months and see the bioscan removal as crucial to further market penetration. Data from over 8000 patients was submitted supporting their case(less 1% had an abnormal scan) and no new trials were required based on discussions with the FDA. Removal of the bioscan reduces the financial burden of treatment, reduce the overall treatment time required from 7-10 days to a short 1-day outpatient procedure. With regards to marketing the drug, additional long-term survival data at ASH 2010 demonstrating robust survival that could also help further adoption among oncologists.
We see additional upside coming later this year with updates on belinostat and apaziquone. They will complete enrollment in a pivotal study for PTCL, begin a rolling NDA filing in 2011 and expect to see Phase 2 data in cancer of unknown primary site in 3Q-2011. Apaziquone top-line results aren’t expected until 2012, but we could see an update at ASCO 2011 in June. We also are excited by their endeavors into developing a biosimilar version of Rituximab, a monoclonal antibody that did $5.6 billion in revenue in 2009. SPPI had more than $100 million going into 2011, which should adequately support their business into 2012, especially with the potential for increased sales of Zevalin and FUSILEV.
CBLI Presentation at 13th Annual BIO CEO & Investor Conference - http://www.ir-site.com/cbiolabs/default.asp
Results of FDA Meeting Regarding FUSILEV(R) sNDA under Review - http://bit.ly/eULkP9
SPPI presentation - http://bit.ly/eEuGwo